Search
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalNerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. … [L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591]
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsQuinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnIt is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. … Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer.
Categories: Heterocyclic Compounds, 2-RingSynonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideScorpion (centruroides) immune Fab2 antivenin (equine)
go.drugbank.com/drugs/DB13905Approved*, *C. l. tecomanus*, and *C. s. suffusus*. … It is intravenously administered patients with clinical signs of scorpion envenomation so that the Fab fragments bind to the toxins and limit systemic toxicity.
Synonyms: Centruroides (scorpion) Immune F(ab')2 (equine), Centruroides (scorpion) immune F(ab')2 (equine) injectionProducts: ALVENO AC 10 ML IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET FLAKON+1 ADET ÇÖZÜCÜ AMPUL, ACSERA 5 ML ENJEKSIYONLUK COZELTI KONSANTRESI ICEREN FLAKONAntihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalPEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein. … Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].
Categories: Compounds used in a research, industrial, or household settingProducts: ADYNOVATE®250IU/VIAL, ADYNOVATE 500®IU / VIALDeflazacort
go.drugbank.com/drugs/DB11921ApprovedDeflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). … [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.
Synonyms: 5'H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-, (11.BETA.,16.BETA.)-, 11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].
Mixtures: SITAGLIPTIN E METFORMINA GALENICUM, SITAGLIPTIN E METFORMINA GALENICUMCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesGrapiprant
go.drugbank.com/drugs/DB12836InvestigationalVet approvedGrapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. … These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin receptor antagonists.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigational[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved … Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDurlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigationalDurlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023.
Synonyms: (2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE, SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTERTrofinetide
go.drugbank.com/drugs/DB06045Approved[A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … , making trofinetide the first and only treatment approved for Rett syndrome in the European Union.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: glycyl-L-2-methylprolyl-L-glutamic acid